SCHEDULE: Fuller & Thaler Reports 5.03% Stake in Collegium Pharma

Fuller & Thaler Asset Management, Inc. has disclosed a beneficial ownership of 5.03% in Collegium Pharmaceutical, Inc. common stock as of June 30, 2026.

Summary

• Fuller & Thaler Asset Management, Inc. has filed a Schedule 13G, indicating they beneficially own 1,632,780.71 shares of Collegium Pharmaceutical, Inc. common stock.
• This ownership stake represents 5.03% of the class of securities.
• The filing date for this event is June 30, 2026.
• Fuller & Thaler Asset Management, Inc. acts as an investment adviser to certain persons who have the right to receive or direct dividends and sale proceeds.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a passive ownership stake reaching a threshold, rather than indicating active strategic involvement or significant performance changes.

Positives

• Fuller & Thaler Asset Management, Inc. has taken a significant, albeit passive, ownership position in Collegium Pharmaceutical, Inc., potentially signaling confidence in the company's long-term prospects.
• The ownership stake of 5.03% crosses the reporting threshold, making this information publicly available.

Negatives

• The filing is a Schedule 13G, which typically indicates passive investment rather than active engagement or a change in control, suggesting no immediate strategic shift is being driven by this entity.
• The filing does not provide any specific performance metrics or forward-looking statements from Fuller & Thaler Asset Management, Inc. regarding Collegium Pharmaceutical, Inc.

Risks

• As an investment adviser, Fuller & Thaler's clients' investment decisions could lead to future changes in ownership, potentially impacting Collegium Pharmaceutical, Inc.'s stock stability.
• The passive nature of the investment means that while a significant stake is held, there's no guarantee of continued support or strategic alignment with Collegium Pharmaceutical, Inc.'s management.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Fuller & Thaler Asset Management, Inc. regarding Collegium Pharmaceutical, Inc.

Industry Context

StockSavvy.ai notes that the pharmaceutical industry, particularly in specialized areas like pain management where Collegium operates, often sees significant institutional investment. Schedule 13G filings by asset managers are common as they cross ownership thresholds, reflecting ongoing portfolio management rather than a specific event or strategic shift concerning the issuer.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lead to greater stock liquidity and potentially more analyst coverage, but the passive nature of this filing suggests no immediate impact on control or strategy.
• Management of Collegium Pharmaceutical, Inc.: Awareness of a significant institutional investor crossing the reporting threshold.
• Other Investors: Provides transparency on a substantial ownership block, aiding in market analysis.

Next Steps

• Monitor future filings from Fuller & Thaler Asset Management, Inc. for any changes in their ownership stake in Collegium Pharmaceutical, Inc.
• Observe Collegium Pharmaceutical, Inc.'s performance and strategic announcements for potential correlation with institutional investor activity.

Key Dates

Keywords

Collegium Pharmaceutical, Fuller & Thaler Asset Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Ownership Threshold